{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:59:53Z","timestamp":1792688393392,"version":"4.5.0"},"reference-count":18,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>No evidence of disease activity (NEDA-3) is a patient-centric outcome increasingly used as the goal of multiple sclerosis treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Determine treatment durability of cladribine tablets beyond 2\u2009years considering the variable bridging interval of 0.1\u2013116.0\u2009weeks between CLARITY and CLARITY Extension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Between CLARITY and CLARITY Extension, patients transitioned from cladribine tablets 3.5\u2009mg\/kg to placebo (CP3.5 group, n\u2009=\u200998) or continued further treatment with cladribine tablets 3.5\u2009mg\/kg (CC7.0 group, n\u2009=\u2009186). Treatment assignment was randomized and blinded in both CLARITY and CLARITY Extension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The 2-year NEDA-3 in CLARITY Extension (encompassing both years of CLARITY Extension) was 29.6% in the CP3.5 group and 32.8% in the CC7.0 group. There was no evidence that treatment effect differed with varying bridging intervals. For patients in the CP3.5 group with a bridging interval of \u2a7d48\u2009weeks, 1\u2009year NEDA-3 (the first year of CLARITY Extension) was 44.4% (28\/63) compared with 31.4% (11\/35) in patients with a bridging interval of &gt;48\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Treatment with cladribine tablets in CLARITY, followed by either placebo or cladribine tablets in CLARITY Extension, produced sustained benefits for NEDA-3 and its constituent elements for a follow up period up to 6\u2009years from CLARITY baseline.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585211049392","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T05:20:26Z","timestamp":1634016026000},"page":"1219-1228","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":32,"title":["Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study"],"prefix":"10.1177","volume":"28","author":[{"given":"Gavin","family":"Giovannoni","sequence":"first","affiliation":[{"name":"Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A","family":"Singer","sequence":"additional","affiliation":[{"name":"The MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Issard","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Cytel Inc., Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Jack","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Neurology and Immunology, Merck Serono Ltd, Feltham, UK (an affiliate of Merck KGaA)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"bibr1-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70021-3"},{"key":"bibr2-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2015.04.006"},{"key":"bibr3-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5486"},{"key":"bibr4-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2012.12.001"},{"key":"bibr5-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2011.08.001"},{"key":"bibr6-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1177\/1756285614560733"},{"key":"bibr7-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515616701"},{"key":"bibr8-13524585211049392","unstructured":"MAVENCLAD 10 mg tablets SmPC. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf"},{"key":"bibr9-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0573-4"},{"key":"bibr10-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70023-0"},{"key":"bibr11-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"bibr12-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"bibr13-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617753365"},{"key":"bibr14-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004354"},{"key":"bibr15-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004313"},{"key":"bibr16-13524585211049392","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00775-9"},{"key":"bibr17-13524585211049392","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1352458520974938","volume":"26","author":"Comi G","year":"2020","journal-title":"Mult Scler"},{"key":"bibr18-13524585211049392","first-page":"935019","volume":"13","author":"Soelberg S\u00f8rensen P","year":"2020","journal-title":"Ther Adv Neurol Dis"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585211049392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585211049392","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585211049392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:07:51Z","timestamp":1777694871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585211049392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1177\/13524585211049392"],"URL":"https:\/\/doi.org\/10.1177\/13524585211049392","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]}}}